News | April 28, 2015

Infraredx Lipid-Rich Plaque Study Reaches 1,000 Patients Enrolled

Researchers hope to find correlation between lipid-rich plaques and occurrence of heart attacks via near-infrared spectroscopy and intravascular ultrasound

Infraredx, LRP Study, TVC Imaging System, Lipid-Rich Plaques, 1,000 patients

The Infraredx system combines IVUS with spectroscopy, which shows a halo ring of color, with yellow being plaque and red representing lipid core plaques based on the chemical composition.


April 28, 2015 — Infraredx Inc. announced the enrollment of 1,000 patients in the Lipid-Rich Plaque (LRP) Study. The LRP Study is a prospective, multi-center clinical trial designed to identify a correlation between lipid-rich plaques detected by Infraredx’s TVC Imaging System and the occurrence of a cardiac event within two years. The first-in-class dual-modality intravascular imaging system integrates near-infrared spectroscopy (NIRS) with intravascular ultrasound (IVUS) technology, allowing clinicians the ability to assess vessel structure and plaque composition. The TVC Imaging System is U.S. Food and Drug Administration (FDA)-approved to identify lipid-core plaques that may cause heart attacks. Identification of such plaques would be a major step toward the development of percutaneous coronary intervention (PCI) as a means to prevent coronary events.

Current PCI imaging technologies are limited in the information they can provide about non-flow limiting plaques that may be dangerous. The results of TVC imaging are presented in the form of a chemogram, an easy-to-read roadmap of cholesterol throughout the vessel scanned. Several prior studies in patients who have already experienced a coronary event have revealed a prominent signal detected by NIRS at the site of the culprit lesion. These studies led to the initiation of the LRP Study to test the hypothesis that a plaque with a large lipid core identified by NIRS imaging is a vulnerable plaque likely to cause a future coronary event. The goal is to prove that vulnerable plaques can be identified by NIRS and provide a target for personalized therapy to prevent coronary events. 

“With 1,000 patients enrolled at 41 investigator sites across the United States and Europe, we are excited by the rapid progress of the LRP Study,” said Ron Waksman, M.D., principal investigator of the LRP Study. “Once complete, the LRP Study data could redefine the role of intravascular imaging and lay the groundwork for changing standard protocols for managing coronary artery disease.”

For more information: www.infraredx.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now